A Phase 3 Study to Evaluate the Efficacy and Safety of TNX-102 SL Taken Daily in Patients With Fibromyalgia
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- Gregory Sullivan, MD
Tonix Pharmaceuticals, Inc.
Study Director
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
33 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Tonix Clinical Site
Phoenix, Arizona, United States
- Tonix Clinical Site
Oceanside, California, United States
- Tonix Clinical Site
Santa Ana, California, United States
- Tonix Clinical Site
Temecula, California, United States
- Tonix Clinical Site
Cromwell, Connecticut, United States
- Tonix Clinical Site
Fort Myers, Florida, United States
- Tonix Clinical Site
Jacksonville, Florida, United States
- Tonix Clinical Site
Miami Lakes, Florida, United States
- Tonix Clinical Site
Ocala, Florida, United States
- Tonix Clinical Site
Oldsmar, Florida, United States
- Tonix Clinical Site
Orlando, Florida, United States
- Tonix Clinical Site
Alpharetta, Georgia, United States
- Tonix Clinical Site
Atlanta, Georgia, United States
- Tonix Clinical Site
Evansville, Indiana, United States
- Tonix Clinical Site
West Des Moines, Iowa, United States
- Tonix Clinical Site
Prairie Village, Kansas, United States
- Tonix Clinical Site
Covington, Louisiana, United States
- Tonix Clinical Site
New Orleans, Louisiana, United States
- Tonix Clinical Site
Prairieville, Louisiana, United States
- Tonix Clinical Site
Boston, Massachusetts, United States
- Tonix Clinical Site
Gulfport, Mississippi, United States
- Tonix Clinical Site
Albuquerque, New Mexico, United States
- Tonix Clinical Site
Williamsville, New York, United States
- Tonix Clinical Site
Cincinnati, Ohio, United States
- Tonix Clinical Site
Tulsa, Oklahoma, United States
- Tonix Clinical Site
Portland, Oregon, United States
- Tonix Clinical Site
Charleston, South Carolina, United States
- Tonix Clinical Site
Austin, Texas, United States
- Tonix Clinical Site
Dallas, Texas, United States
- Tonix Clinical Site
McKinney, Texas, United States
- Tonix Clinical Site
Charlottesville, Virginia, United States
- Tonix Clinical Site
Danville, Virginia, United States
- Tonix Clinical Site
Kenosha, Wisconsin, United States
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 6 Apr 2022
- Primary completion
- 14 Nov 2023
- Completion
- 14 Nov 2023
- Last update posted
- 22 Jan 2025
- Registered enrollment
- 457
- Registry id
- NCT05273749
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.